HEADER OXIDOREDUCTASE 27-JUL-06 2DUZ TITLE HUMAN ALDOSE REDUCTASE COMPLEXED WITH INHIBITOR ZOPOLRESTAT AFTER 3 TITLE 2 DAYS SOAKING (3DAYS_SOAKED_2) COMPND MOL_ID: 1; COMPND 2 MOLECULE: ALDOSE REDUCTASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: AR, ALDEHYDE REDUCTASE; COMPND 5 EC: 1.1.1.21; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21 GOLD; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET 15B KEYWDS TIM-BARREL, OXIDOREDUCTASE EXPDTA X-RAY DIFFRACTION AUTHOR H.STEUBER,A.HEINE,G.KLEBE REVDAT 5 25-OCT-23 2DUZ 1 REMARK REVDAT 4 24-FEB-09 2DUZ 1 VERSN REVDAT 3 17-OCT-06 2DUZ 1 REMARK REVDAT 2 10-OCT-06 2DUZ 1 JRNL REVDAT 1 03-OCT-06 2DUZ 0 JRNL AUTH H.STEUBER,M.ZENTGRAF,C.GERLACH,C.A.SOTRIFFER,A.HEINE,G.KLEBE JRNL TITL EXPECT THE UNEXPECTED OR CAVEAT FOR DRUG DESIGNERS: MULTIPLE JRNL TITL 2 STRUCTURE DETERMINATIONS USING ALDOSE REDUCTASE CRYSTALS JRNL TITL 3 TREATED UNDER VARYING SOAKING AND CO-CRYSTALLISATION JRNL TITL 4 CONDITIONS JRNL REF J.MOL.BIOL. V. 363 174 2006 JRNL REFN ISSN 0022-2836 JRNL PMID 16952371 JRNL DOI 10.1016/J.JMB.2006.08.011 REMARK 2 REMARK 2 RESOLUTION. 1.60 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.60 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 50.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 80.4 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.162 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.164 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.221 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 1696 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 34368 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.153 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE (F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 28365 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2517 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 77 REMARK 3 SOLVENT ATOMS : 337 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 2939.0 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 2525.0 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 13 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 12005 REMARK 3 NUMBER OF RESTRAINTS : 11046 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 ANGLE DISTANCES (A) : 2.500 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.028 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.060 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.063 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.023 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.000 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.069 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.000 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: ANISOTROPIC SCALING APPLIED BY THE REMARK 3 METHOD OF PARKIN, MOEZZI & HOPE, J.APPL.CRYST.28(1995)53-56 REMARK 4 REMARK 4 2DUZ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 28-JUL-06. REMARK 100 THE DEPOSITION ID IS D_1000025875. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 16-SEP-05 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU300 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : GRAPHITE REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 35051 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.600 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 86.3 REMARK 200 DATA REDUNDANCY : 2.500 REMARK 200 R MERGE (I) : 0.04900 REMARK 200 R SYM (I) : 0.04900 REMARK 200 FOR THE DATA SET : 23.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.60 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.63 REMARK 200 COMPLETENESS FOR SHELL (%) : 62.1 REMARK 200 DATA REDUNDANCY IN SHELL : 2.10 REMARK 200 R MERGE FOR SHELL (I) : 0.27000 REMARK 200 R SYM FOR SHELL (I) : 0.27000 REMARK 200 FOR SHELL : 3.400 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: PDB ENTRY 1EL3 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 43.12 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.18 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 25% PEG 6000, 120MM CITRATE BUFFER, PH REMARK 280 5.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 33.55000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE ASYMMETRIC UNIT CONTAINS ONE BIOLOGICAL UNIT (MONOMER). REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 0 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 69 NE - CZ - NH1 ANGL. DEV. = 3.9 DEGREES REMARK 500 GLU A 120 O - C - N ANGL. DEV. = -10.9 DEGREES REMARK 500 TYR A 209 CB - CG - CD1 ANGL. DEV. = 3.7 DEGREES REMARK 500 TYR A 209 CG - CD1 - CE1 ANGL. DEV. = 5.5 DEGREES REMARK 500 ARG A 217 NE - CZ - NH1 ANGL. DEV. = 3.6 DEGREES REMARK 500 HIS A 306 CG - ND1 - CE1 ANGL. DEV. = 7.4 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 21 2.88 80.25 REMARK 500 ARG A 293 15.67 -140.98 REMARK 500 ALA A 299 68.19 -174.86 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NAP A 500 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ZST A 600 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2FZ8 RELATED DB: PDB REMARK 900 HUMAN ALDOSE REDUCTASE COMPLEXED WITH INHIBITOR ZOPOLRESTAT AT 1.48 REMARK 900 A(1 DAY SOAKING) REMARK 900 RELATED ID: 2FZ9 RELATED DB: PDB REMARK 900 HUMAN ALDOSE REDUCTASE COMPLEXED WITH INHIBITOR ZOPOLRESTAT AFTER REMARK 900 SIX DAYS SOAKING REMARK 900 RELATED ID: 2DUX RELATED DB: PDB REMARK 900 HUMAN ALDOSE REDUCTASE COMPLEXED WITH INHIBITOR ZOPOLRESTAT AFTER 3 REMARK 900 DAYS SOAKING (3DAYS_SOAKED_1) REMARK 900 RELATED ID: 2DV0 RELATED DB: PDB REMARK 900 HUMAN ALDOSE REDUCTASE COMPLEXED WITH INHIBITOR ZOPOLRESTAT AFTER 6 REMARK 900 DAYS SOAKING(6DAYS_SOAKED_2) DBREF 2DUZ A 0 315 UNP P15121 ALDR_HUMAN 1 316 SEQADV 2DUZ ILE A 4 UNP P15121 LEU 4 SEE REMARK 999 SEQRES 1 A 316 MET ALA SER ARG ILE LEU LEU ASN ASN GLY ALA LYS MET SEQRES 2 A 316 PRO ILE LEU GLY LEU GLY THR TRP LYS SER PRO PRO GLY SEQRES 3 A 316 GLN VAL THR GLU ALA VAL LYS VAL ALA ILE ASP VAL GLY SEQRES 4 A 316 TYR ARG HIS ILE ASP CYS ALA HIS VAL TYR GLN ASN GLU SEQRES 5 A 316 ASN GLU VAL GLY VAL ALA ILE GLN GLU LYS LEU ARG GLU SEQRES 6 A 316 GLN VAL VAL LYS ARG GLU GLU LEU PHE ILE VAL SER LYS SEQRES 7 A 316 LEU TRP CYS THR TYR HIS GLU LYS GLY LEU VAL LYS GLY SEQRES 8 A 316 ALA CYS GLN LYS THR LEU SER ASP LEU LYS LEU ASP TYR SEQRES 9 A 316 LEU ASP LEU TYR LEU ILE HIS TRP PRO THR GLY PHE LYS SEQRES 10 A 316 PRO GLY LYS GLU PHE PHE PRO LEU ASP GLU SER GLY ASN SEQRES 11 A 316 VAL VAL PRO SER ASP THR ASN ILE LEU ASP THR TRP ALA SEQRES 12 A 316 ALA MET GLU GLU LEU VAL ASP GLU GLY LEU VAL LYS ALA SEQRES 13 A 316 ILE GLY ILE SER ASN PHE ASN HIS LEU GLN VAL GLU MET SEQRES 14 A 316 ILE LEU ASN LYS PRO GLY LEU LYS TYR LYS PRO ALA VAL SEQRES 15 A 316 ASN GLN ILE GLU CYS HIS PRO TYR LEU THR GLN GLU LYS SEQRES 16 A 316 LEU ILE GLN TYR CYS GLN SER LYS GLY ILE VAL VAL THR SEQRES 17 A 316 ALA TYR SER PRO LEU GLY SER PRO ASP ARG PRO TRP ALA SEQRES 18 A 316 LYS PRO GLU ASP PRO SER LEU LEU GLU ASP PRO ARG ILE SEQRES 19 A 316 LYS ALA ILE ALA ALA LYS HIS ASN LYS THR THR ALA GLN SEQRES 20 A 316 VAL LEU ILE ARG PHE PRO MET GLN ARG ASN LEU VAL VAL SEQRES 21 A 316 ILE PRO LYS SER VAL THR PRO GLU ARG ILE ALA GLU ASN SEQRES 22 A 316 PHE LYS VAL PHE ASP PHE GLU LEU SER SER GLN ASP MET SEQRES 23 A 316 THR THR LEU LEU SER TYR ASN ARG ASN TRP ARG VAL CYS SEQRES 24 A 316 ALA LEU LEU SER CYS THR SER HIS LYS ASP TYR PRO PHE SEQRES 25 A 316 HIS GLU GLU PHE HET NAP A 500 48 HET ZST A 600 29 HETNAM NAP NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE HETNAM ZST 3,4-DIHYDRO-4-OXO-3-((5-TRIFLUOROMETHYL-2- HETNAM 2 ZST BENZOTHIAZOLYL)METHYL)-1-PHTHALAZINE ACETIC ACID HETSYN NAP 2'-MONOPHOSPHOADENOSINE 5'-DIPHOSPHORIBOSE FORMUL 2 NAP C21 H28 N7 O17 P3 FORMUL 3 ZST C19 H12 F3 N3 O3 S FORMUL 4 HOH *337(H2 O) HELIX 1 1 PRO A 23 GLY A 38 1 16 HELIX 2 2 ALA A 45 GLN A 49 5 5 HELIX 3 3 ASN A 50 GLU A 64 1 15 HELIX 4 4 LYS A 68 LEU A 72 5 5 HELIX 5 5 TRP A 79 HIS A 83 5 5 HELIX 6 6 GLU A 84 GLY A 86 5 3 HELIX 7 7 LEU A 87 LYS A 100 1 14 HELIX 8 8 ASN A 136 GLU A 150 1 15 HELIX 9 9 ASN A 162 ASN A 171 1 10 HELIX 10 10 GLN A 192 LYS A 202 1 11 HELIX 11 11 SER A 226 GLU A 229 5 4 HELIX 12 12 ASP A 230 ASN A 241 1 12 HELIX 13 13 THR A 243 GLN A 254 1 12 HELIX 14 14 THR A 265 LYS A 274 1 10 HELIX 15 15 SER A 281 TYR A 291 1 11 HELIX 16 16 LEU A 300 THR A 304 5 5 SHEET 1 A 2 ARG A 3 LEU A 5 0 SHEET 2 A 2 LYS A 11 PRO A 13 -1 O MET A 12 N ILE A 4 SHEET 1 B 8 LEU A 17 GLY A 18 0 SHEET 2 B 8 HIS A 41 ASP A 43 1 O ASP A 43 N LEU A 17 SHEET 3 B 8 PHE A 73 LEU A 78 1 O VAL A 75 N ILE A 42 SHEET 4 B 8 LEU A 106 ILE A 109 1 O LEU A 108 N LEU A 78 SHEET 5 B 8 ILE A 156 SER A 159 1 O GLY A 157 N ILE A 109 SHEET 6 B 8 VAL A 181 GLU A 185 1 O VAL A 181 N ILE A 158 SHEET 7 B 8 VAL A 205 TYR A 209 1 O THR A 207 N ILE A 184 SHEET 8 B 8 VAL A 258 VAL A 259 1 O VAL A 258 N ALA A 208 SITE 1 AC1 34 GLY A 18 THR A 19 TRP A 20 LYS A 21 SITE 2 AC1 34 ASP A 43 TYR A 48 HIS A 110 TRP A 111 SITE 3 AC1 34 SER A 159 ASN A 160 GLN A 183 TYR A 209 SITE 4 AC1 34 SER A 210 PRO A 211 LEU A 212 GLY A 213 SITE 5 AC1 34 SER A 214 PRO A 215 ASP A 216 ALA A 245 SITE 6 AC1 34 ILE A 260 PRO A 261 LYS A 262 SER A 263 SITE 7 AC1 34 VAL A 264 THR A 265 ARG A 268 GLU A 271 SITE 8 AC1 34 ASN A 272 CYS A 298 ZST A 600 HOH A1093 SITE 9 AC1 34 HOH A1142 HOH A1149 SITE 1 AC2 14 TRP A 20 TYR A 48 HIS A 110 TRP A 111 SITE 2 AC2 14 THR A 113 PHE A 122 TRP A 219 CYS A 298 SITE 3 AC2 14 LEU A 300 CYS A 303 TYR A 309 PRO A 310 SITE 4 AC2 14 NAP A 500 HOH A1118 CRYST1 49.400 67.100 47.200 90.00 92.80 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.020243 0.000000 0.000990 0.00000 SCALE2 0.000000 0.014903 0.000000 0.00000 SCALE3 0.000000 0.000000 0.021212 0.00000